VST BIO is a biotechnology company that develops antibodies for the treatment of inflammatory and cardiovascular diseases, including stroke and acute myocardial infarction, as well as sepsis.
VST Bio utilizes this new class of therapeutics to control injury-induced inflammation and vascular permeability (and control edema formation) in acute stroke, and other acute cardiovascular disease, dramatically expanding the opportunities for effective medical therapy in stroke patients, in particular for the majority of patients who do not present within the first hours after onset of symptoms, and cannot be treated with conventional standard-of-care medical therapy.
Novel antibody therapeutic for stroke
We are entering clinical trials in 2026 with our novel antibody VB-001 therapeutic for stroke.
Clinical Trials
Poised to revolutionize treatment for a variety of diseases
VST Bio’s team envisions a future where ischemic stroke and myocardial infraction no longer impose a life-threatening tissue damage or progression to neurological dysfunction or heart failure. We are entering clinical trials in 2026 with our novel antibody therapeutic for stroke.
A true game-changer in stroke therapy
Our VST Bio humanized antibody, VB-001, delivered via a simple IV bolus infusion, reverses vascular dysfunction and reduces inflammation in the brain. Vascular leakage is a co-morbidity seen in a variety of diseases including stroke, myocardial infarction, traumatic brain injury, reperfusion injury, ARDS/ COVID-19 infection, and shock. Our antibody therapeautic is poised to change treatment.